Excelsior Medical (4104) is a TW-listed Healthcare company in Medical - Distribution with a market capitalization of NT
3.4B, trading at NT$70.90 on the TAI. This SniperIQ fundamentals page covers Excelsior Medical's valuation (P/E 15.4x, P/B 1.6x), profitability (net margin 9.1%), revenue (NT$8.8B in FY2025), balance-sheet quality, and AI signal context — from live market data, research only.
Market CapNT
3.4B
P/E (TTM)15.4x
Net Margin9.1%
Revenue (FY25)NT$8.8B
Full research coverage
8-Quarter Revenue & Margin Trend
Debt Maturity & Coverage
Peer Valuation Comparison
Free Cash Flow & Owner Earnings
AI Signal + Institutional Flow
DCF Valuation Model
Frequently Asked Questions
What is Excelsior Medical's market cap?
Excelsior Medical (4104) has a market capitalization of approximately NT
3.4B, trading at NT$70.90 on the TAI. Market cap moves with the live share price.
What is Excelsior Medical's P/E ratio?
Excelsior Medical's trailing twelve-month P/E ratio is 15.4x, with a price-to-book (P/B) of 1.6x. Valuation multiples are best compared with Healthcare sector peers rather than read in isolation.
How profitable is Excelsior Medical?
Excelsior Medical runs a net profit margin of 9.1%, a gross margin of 21.3%, and an operating margin of 8.1%. Margins and ROE indicate how efficiently the business converts sales into profit and shareholder returns.
How much revenue does Excelsior Medical generate?
Excelsior Medical reported revenue of NT$8.8B for fiscal year 2025, with net income of NT$806M and earnings per share (EPS) of 4.62. SniperIQ tracks the full 8-quarter revenue and margin trend on the research dashboard.
Does Excelsior Medical pay a dividend?
Excelsior Medical offers a trailing dividend yield of about 6.1%. Dividend sustainability depends on payout ratio, free cash flow, and earnings stability — all tracked in SniperIQ's fundamentals view.
Is Excelsior Medical financially healthy?
Excelsior Medical carries a debt-to-equity ratio of 0.13x and a current ratio of 1.70x, with a market beta of -0.02. Lower leverage and a current ratio above 1.0 generally signal a stronger balance sheet.
Is Excelsior Medical a good stock to buy in 2026?
SniperIQ provides research-only market intelligence, not personalised financial advice or a buy/sell call. For Excelsior Medical (4104) the key facts are: market cap NT
3.4B, P/E 15.4x, revenue NT$8.8B, 52-week range 67.3-86.8. Weigh valuation, profitability, growth, and balance-sheet strength against Healthcare peers and form your own view.
Track Excelsior Medical's full fundamentals live
Get Excelsior Medical's 8-quarter revenue and margin trend, peer comparison, DCF model, and AI signal on the SniperIQ research dashboard.